Minimal stimulation is an alternative to conventional ovarian stimulation with fewer side effects, such as ovarian hyperstimulation syndrome, and better cost-effectiveness since the economic burden due to gonadotropin administration and hospital visits is reduced. 1 Clomiphene citrate (CC) often is administered in minimal ovarian stimulation in vitro fertilization (IVF) treatment. 2-5 CC binds hypothalamic estrogen receptors and induces endogenous gonadotropin-releasing hormone (GnRH) secretion by altering the negative feedback effect Abstract Purpose: Exogenous gonadotropins (EGn) have been used occasionally in clomiphene citrate (CC)-based minimal stimulation cycles to compensate insufficient secretion of endogenous gonadotropin; however, the effectiveness of EGn supplementation remains unknown. In the present study, we assessed whether EGn improved pregnancy outcomes in CC-based minimal stimulation cycles.
of estrogen on the hypothalamus. Clinically, in minimal ovarian stimulation IVF, CC is usually administered alone. However, the minimal necessary follicle-stimulating hormone (FSH) or human menopausal gonadotropin (hMG) are administered occasionally in the late follicular stage in CC-based minimal stimulation cycles. 6 In some cases, multiple follicles develop simultaneously after CC administration. Thus, the serum levels of estradiol, which is produced in the granulosa cells in follicles, substantially increase. The estradiol binds to the estrogen receptors in the hypothalamus and downregulates the secretion of gonadotropins from the pituitary. 7 If the negative feedback occurs at the mid-follicular phase, it might lead to insufficient secretion of endogenous FSH and luteinizing hormone (LH), which are required to induce final maturation in the multiple follicles; therefore, exogenous gonadotropins (EGn) have been administered to compensate for the insufficient endogenous FSH and LH secretion, after monitoring serum hormone levels and follicular growth using ultrasound scans, to induce maturation of multiple oocytes. 6, 8 Therefore, administering FSH or hMG in a CC-based minimal stimulation regimen is considered to improve the oocyte retrieval result followed by IVF outcomes.
Follicle-stimulating hormone and hMG have been used often for controlled ovarian hyperstimulation (COH) cycles, and the effectiveness of the use of FSH and hMG in COH cycles has been shown worldwide. However, to our knowledge, there are no available studies that have investigated embryonic and pregnancy outcomes in minimal stimulation cycle IVF using CC alone or CC and FSH or hMG. Therefore, in the present study, we retrospectively assessed whether the administration of FSH and hMG improved embryonic and pregnancy outcomes in minimal stimulation cycles.
| MATERIAL S AND ME THOD

| Study patients
In our clinic, assisted reproductive technology is the first choice of any fertility treatment strategy. A total of 3888 patients who underwent oocyte retrieval during CC-based minimal stimulation cycles between January 2016 and December 2016 at Kato Ladies Clinic were available for analysis, which included 3657 patients who received CC only (CC group) and 231 patients who received CC with EGn (CC-EGn group).
After propensity score matching, 223 patients in the CC-EGn group were matched one to one to patients in the CC group ( Figure 1 ). The present study only included patients aged 30-39 years at time of oocyte retrieval. Patients presenting with recurrent implantation failure, that is, those who previously underwent embryo transfer four or more times, 9 and patients who had ovulation disorder were excluded.
| Minimal ovarian stimulation cycle in vitro fertilization
The ovarian stimulation method is usually decided through consultation with patients, with patient preferences taken into account. The detailed protocol for CC-based minimal stimulation with CC alone has been reported previously. 10 Briefly, CC (50 mg/d; Fuji Pharma Co., Ltd) was orally administered with an extended regimen, starting on day 3 of the retrieval cycle to the day before induction of final oocyte maturation. Monitoring, which involved an ultrasound scan and hormonal profiles, was usually initiated on day 8 and was performed continuously every other day until the ovulation triggering day. Ovulation triggering was performed using a nasal spray containing the GnRH agonist buserelin (Suprecur; Mochida Pharmaceutical Co., Ltd. or Buserecur; Fuji Pharma Co., Ltd.). A minimal dose of hMG (Ferring Pharma Co., Ltd) or recombinant FSH (rFSH: Merck & Co.) was administered on days 8 and 10 to induce final follicular growth and maturation when (a) there were more than three follicles of uniform size (smaller than 10 mm) in the ovary on the day 8 and (b) the serum FSH level was less than 15 mIU/mL. 6, 8 When the serum FSH level was less than 10 mIU/mL, 150 IU of either hMG or rFSH was administered. When the serum FSH level on day 8 was 10-15 mIU/ mL, 75 IU of hMG or rFSH was administered.
Oocyte retrieval was usually performed 30-36 hours after triggering using a 21-G needle (Kitazato Corporation), generally without anesthesia or follicular flushing. Cumulus-oocyte complexes (COCs) were collected, washed, and then transferred to human tubal fluid (HTF) medium (Kitazato Corporation) with paraffin oil at 5% CO2 in air at 37˚C. These were cultured until use in either conventional IVF (cIVF) 3 hours later or denudation for cases of intracytoplasmic sperm injection (ICSI) 4 hours after oocyte retrieval. 11 For ICSI, cumulus cells surrounding the oocytes were removed, and the denuded oocytes were cultured in HTF medium covered by paraffin oil for 1 hour before ICSI. Sperm samples were collected by masturbation and washed by centrifugation through 70% and 90% density gradients (Isolate; Irvine Scientific). Prepared sperm was cultured in HTF medium at 5% CO 2 in air at 37°C until use.
| Conventional insemination, intracytoplasmic sperm injection, embryo culture, and cryopreservation
Conventional insemination or intracytoplasmic sperm injection was performed approximately 3 and 5 hours after oocyte retrieval, respectively. 12 For cases of cIVF, HTF medium supplemented with 10% serum substitute (Irvine Scientific) was used as a fertilization medium. COCs were cultured with sperm (100 000 sperm/mL) at 5% CO 2 in air at 37°C. Fertilization assessment was performed 16-20 hours after insemination. Normally, fertilized zygotes with two pronuclei were individually cultured in the embryo culture medium (Sage One-step: Origio a/s). In cases of ICSI, oocytes were immediately placed into embryo culture medium, and fertilization was confirmed in the morning of day 1. All embryos were cultured at 37˚C (gas phase: 5% O 2 , 5% CO 2 , and 90% N 2 ), in 100% humidity in a water jacket or non-humidified incubator (Astec Co. Ltd.). The embryos were cultured to the cleavage or blastocyst stage and vitrified for subsequent use in embryo transfer cycles. The embryo vitrification was performed using Cryotop ® (Kitazato Biopharma), as described previously. 13 
| Embryo transfer
During the study period, single embryo transfers were performed exclusively. Fresh or vitrified-warmed embryo transfers were performed in spontaneous natural or hormonal replacement cycles as previously described. 6, 12, 14, 15 Cleaved embryo and blastocyst transfers were performed on days 2-3 and day 5 after oocyte retrieval or the confirmation of ovulation, respectively. Dydrogesterone (30 mg/d) was routinely orally administered during the early luteal phase after the embryo transfer procedure. In addition, in cases with insufficient luteal function, progesterone was administered intravaginally (Lutinus, Ferring Pharmaceuticals) until the ninth week of pregnancy. The clinical pregnancy rate and ongoing pregnancy rate were defined according to the ultrasonographic observation of a gestational sac at 5-6 weeks after embryo transfer and observation of fetal heartbeats at 7 weeks after embryo transfer, respectively.
| Statistical analyses
In the present study, to reduce the bias of patient characteristics, a propensity score matching was performed using JMP software (SAS). All statistical analyses were performed using JMP software.
Continuous parameters were compared via a student's t test. 
| RE SULTS
| Patient characteristics
In this cohort, 3888 patients who underwent oocyte retrieval during CC-based minimal stimulation cycles were available for analysis ( Figure 1 ). There were 3657 patients who received CC only (CC group) and 231 patients who received CC with EGn (CC-EGn group). After propensity score matching, 223 patients in the CC-EGn group were matched one to one to patients in the CC group. Before propensity score matching, some patient characteristics, such as women's age, men's age, infertility cause, and basal estradiol level, varied significantly between the two groups ( Table 1 ). After propensity score matching, the 223 matched pairs were analyzed for differences in patient baseline characteristics (Table 1 and Figure 1 ).
There were no significant differences in the characteristics between the two matched groups.
| In vitro fertilization outcomes
The total dose of CC in the CC group (461.2 ± 6.0 [300-750] mg) was lower than that in the CC-EGn group (614.6 ± 8.4 [250-950] IU) ( Table 2 ). The total EGn dose was 291.9 ± 7.4 [75-450] IU.
The number of oocytes retrieved and inseminated was increased significantly in the CC-EGn group than in the CC group (Table 2 ).
An increased number of fertilized oocytes and cleaved embryos were obtained in the CC-EGn group than in the CC group, although fertilization and cleavage rates were statistically comparable between the two groups. Furthermore, the number of cryopreserved blastocysts was higher in the CC-EGn group than in the CC group (0.6 ± 0.1 vs 1.2 ± 0.1, P < .0001). On the other hand, the blastocyst cryopreservation rate was significantly lower in the CC-EGn group than in the CC group (67.3% vs 58.2%, P = .0251).
| Pregnancy outcomes
The rates of clinical pregnancy, ongoing pregnancy, and live birth after fresh cleaved embryo transfers were comparable between the two groups ( Table 3 ). The live birthrate after a frozen cleaved embryo transfer in the CC-EGn group was lower than that in the CC group, although there were no differences in the clinical and ongoing pregnancy rates between the groups. The pregnancy outcomes after frozen blastocyst transfer were comparable between the two groups. The cumulative live birthrate in the CC-EGn group was similar to that in the CC group. Furthermore, we analyzed the correlation between the number of retrieved oocytes and the cumulative live birthrate. In the CC group, the increased number of retrieved oocytes was significantly correlated with improvement of the cumulative live birthrate (OR, 1.553; 95% CIs, 1.223-1.948; P = .0003; AUC, 0.663). The oocyte number in the CC-EGn group also was associated with the cumulative birthrate (OR, 1.193; 95% CIs, 1.086-1.325; P = .0005; AUC, 0.667). When the cumulative birthrate was stratified by the oocyte number, no significant differences were observed between the groups, although the rates in the CC group were numerically higher than those in the CC-EGn group (Table S1 ). In addition, clinical studies have reported that the live birthrate per oocyte in natural cycles of IVF was higher than that in a controlled ovarian stimulation cycle, suggesting that aggressive ovarian stimulation is likely to yield a high number of oocytes that will not result in a live birth. 21, 22 have reported that CC could adversely affect uterine receptivity and pregnancy outcomes during fresh embryo transfer cycles. 10, 23 Furthermore, gonadotropin administration for ovarian stimulation impacts uterine receptivity. [24] [25] [26] Therefore, if the embryo transfer method was comparable between the two groups, the results of the statistical analysis might be changed.
TA B L E 1 Patients' characteristics
| D ISCUSS I ON
In conclusion, the cumulative live birthrate for patients with insufficient secretion of endogenous gonadotropin induced by multiple follicle development after CC administration could be rescued by EGn administration in the late follicular phase after monitoring the follicular growth and serum hormone levels. Therefore, when CCbased minimal stimulation cycle IVF is performed, the stimulation should be started with CC only, and EGn administration should be scheduled only if insufficient secretion of endogenous gonadotropin is observed in the late follicular phase.
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